ORLANDO, Fla.–(BUSINESS WIRE)– #Alzheimers–Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI…
Author: Business Wire
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
PARIS–(BUSINESS WIRE)–Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing i…
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the c…
Vision Loss Takes an Emotional Toll. Hadley Is Addressing It.
WINNETKA, Ill.–(BUSINESS WIRE)– #HadleyHelps–Hadley’s free video series on the emotional impact of vision loss draws its strongest early response, pointing to a gap in vision care.
Credo Launches 800G ZeroFlap Optical Transceivers Engineered for AI Networks
SAN JOSE, Calif.–(BUSINESS WIRE)– #WeConnect–Credo launches 800G ZeroFlap optical transceivers engineered for AI networks.
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete…
Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
GENEVA–(BUSINESS WIRE)–Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
Neurotech Provides Corporate Update on Commercial Progress
CUMBERLAND, R.I.–(BUSINESS WIRE)–Neurotech Pharmaceuticals, Inc. (the “Company”) today provided an update on its ongoing transition to a commercial‑stage company following the first anniversary of the FDA’s approval of ENCELTO™ (taroretcel-lwey), the…
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
JACKSONVILLE, Fla.–(BUSINESS WIRE)–Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
Heru Showcases PretestPro™ for the Heru VR-Powered Diagnostic Headset at Vision Expo
MIAMI–(BUSINESS WIRE)– #AIPoweredVisionDiagnostics–Heru, the leader in AI-powered vision diagnostics, announced it is showcasing the new PretestPro on its Heru wearable platform at Vision Expo 2026.
Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #AurionBiotech–Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today a…
Sightview Unveils Fresh Patient Engagement Tools at Vision Expo 2026
DURHAM, N,C.–(BUSINESS WIRE)– #Automation–Sightview will showcase two recently updated tools for its eyecare-specific EHR/PM offering at Vision Expo 2026. See demos in booth #4021.
National Vision Announces Winners of 11th Annual Scholarship Program
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Announces Winners of 11th Annual Scholarship Program
Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive Officer
DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (C…
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series that will …
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics fait le point sur les programmes d’accès précoce de GS010/LUMEVOQ® et sur l’étude REVISE en cours
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique en phase clinique, spécialisée dans le développement et la comme…
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious med…
Lucidis® établit des normes élevées en matière de chirurgie de la cataracte haut de gamme grâce à des performances visuelles complètes
NEUCHÂTEL, Suisse–(BUSINESS WIRE)–Swiss Advanced Vision annonce de nouvelles preuves cliniques confirmant les performances exceptionnelles de sa lentille intraoculaire Lucidis®, renforçant ainsi sa position de solution novatrice en chirurgie de la ca…
National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2025 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the fourth quarter and fiscal year ended January 3, 2026, and is providing its outlook for fiscal 2…